Calidi Biotherapeutics, Inc. — Form 8-K Summary
Reporting date: September 17, 2026; the offering closed on September 21, 2026. The filing was signed on September 22, 2026.
Business Context and Transaction
Calidi Biotherapeutics entered into a securities purchase agreement with accredited investors and/or qualified institutional buyers for a registered direct offering of common stock. The company issued 1,025,640 shares at $1.17 per share pursuant to its effective Form S-3 shelf registration statement.
Financial and Capitalization Impact
- Gross proceeds: Approximately $1.2 million, before offering expenses.
- Net proceeds: Not specified in the filing.
- Use of proceeds: Working capital and general corporate purposes.
- Fees: No underwriter, placement agent, broker-dealer, or similar fees or commissions were paid.
- Operating metrics: The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other periodic financial results.
- Capitalization: The offering increased shares outstanding by 1,025,640 shares; the filing text does not provide a resulting total share count or quantified dilution percentage.
Material Changes and Terms
- The company raised approximately $1.2 million through a registered direct equity offering.
- For 45 days after closing, the company agreed, subject to specified exceptions, not to issue or sell equity or equity-linked securities without consent from purchasers holding more than 50% of the shares purchased under the agreement.
- Directors and executive officers entered into customary 60-day lock-up agreements covering their common stock and related securities.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or operating outlook was provided. The primary disclosed risk is the company’s need to fund working capital and general corporate activities with a relatively small equity raise. The transaction may result in dilution to existing shareholders, and the short-term issuance restriction and insider lock-ups may affect the company’s financing flexibility. The filing does not describe specific contingencies or unusual operating items.
Investor Verification Items
- Verify the final net proceeds after offering expenses and the company’s post-offering cash balance and liquidity runway.
- Confirm the total shares outstanding after issuance and the resulting ownership dilution.
- Review the full securities purchase agreement for exceptions to the 45-day issuance restriction and other investor rights.
- Review the Form S-3 prospectus supplement and related exhibits, including the legal opinion and September 17, 2026 press release.
- Assess whether the proceeds are sufficient to support planned operations or whether additional financing may be required.